JP2005530732A5 - - Google Patents

Download PDF

Info

Publication number
JP2005530732A5
JP2005530732A5 JP2003584094A JP2003584094A JP2005530732A5 JP 2005530732 A5 JP2005530732 A5 JP 2005530732A5 JP 2003584094 A JP2003584094 A JP 2003584094A JP 2003584094 A JP2003584094 A JP 2003584094A JP 2005530732 A5 JP2005530732 A5 JP 2005530732A5
Authority
JP
Japan
Prior art keywords
glp
pharmaceutical composition
composition according
compound
derivative
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2003584094A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005530732A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2003/008457 external-priority patent/WO2003087139A2/en
Publication of JP2005530732A publication Critical patent/JP2005530732A/ja
Publication of JP2005530732A5 publication Critical patent/JP2005530732A5/ja
Pending legal-status Critical Current

Links

JP2003584094A 2002-04-10 2003-03-27 胃不全麻痺の治療 Pending JP2005530732A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37165002P 2002-04-10 2002-04-10
PCT/US2003/008457 WO2003087139A2 (en) 2002-04-10 2003-03-27 Treatment of gastroparesis

Publications (2)

Publication Number Publication Date
JP2005530732A JP2005530732A (ja) 2005-10-13
JP2005530732A5 true JP2005530732A5 (OSRAM) 2006-05-18

Family

ID=29250714

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003584094A Pending JP2005530732A (ja) 2002-04-10 2003-03-27 胃不全麻痺の治療

Country Status (18)

Country Link
US (1) US20050164925A1 (OSRAM)
EP (1) EP1496924A4 (OSRAM)
JP (1) JP2005530732A (OSRAM)
KR (1) KR20040098063A (OSRAM)
CN (1) CN1735423A (OSRAM)
AU (1) AU2003220403A1 (OSRAM)
BR (1) BR0308904A (OSRAM)
CA (1) CA2480858A1 (OSRAM)
EA (1) EA200401345A1 (OSRAM)
EC (1) ECSP045345A (OSRAM)
HR (1) HRP20040939A2 (OSRAM)
IL (1) IL164266A0 (OSRAM)
MX (1) MXPA04009929A (OSRAM)
NO (1) NO20044815L (OSRAM)
NZ (1) NZ535684A (OSRAM)
PL (1) PL373658A1 (OSRAM)
WO (1) WO2003087139A2 (OSRAM)
ZA (1) ZA200408111B (OSRAM)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8666495B2 (en) 1999-03-05 2014-03-04 Metacure Limited Gastrointestinal methods and apparatus for use in treating disorders and controlling blood sugar
US9101765B2 (en) 1999-03-05 2015-08-11 Metacure Limited Non-immediate effects of therapy
US8792985B2 (en) 2003-07-21 2014-07-29 Metacure Limited Gastrointestinal methods and apparatus for use in treating disorders and controlling blood sugar
JP2007537981A (ja) 2003-09-19 2007-12-27 ノボ ノルディスク アクティーゼルスカブ 新規の血漿タンパク質親和性タグ
TW200526254A (en) * 2003-09-19 2005-08-16 Novo Nordisk As Novel GLP-1 derivatives
EP1793891B1 (en) 2004-08-18 2011-11-09 Metacure Limited Monitoring, analysis, and regulation of eating habits
US9339190B2 (en) 2005-02-17 2016-05-17 Metacure Limited Charger with data transfer capabilities
US9821158B2 (en) 2005-02-17 2017-11-21 Metacure Limited Non-immediate effects of therapy
TWI362392B (en) 2005-03-18 2012-04-21 Novo Nordisk As Acylated glp-1 compounds
MX2007011307A (es) 2005-03-18 2007-10-08 Novo Nordisk As Compuestos de glp-1 extendidos.
US8463404B2 (en) 2005-03-24 2013-06-11 Metacure Limited Electrode assemblies, tools, and methods for gastric wall implantation
US8265758B2 (en) * 2005-03-24 2012-09-11 Metacure Limited Wireless leads for gastrointestinal tract applications
US8301256B2 (en) 2005-06-02 2012-10-30 Metacure Limited GI lead implantation
US8442841B2 (en) * 2005-10-20 2013-05-14 Matacure N.V. Patient selection method for assisting weight loss
US8295932B2 (en) 2005-12-05 2012-10-23 Metacure Limited Ingestible capsule for appetite regulation
AU2012203915B9 (en) * 2006-04-20 2014-10-09 Amgen Inc. GLP-1 compounds
CA2800389A1 (en) * 2006-04-20 2007-11-01 Amgen Inc. Glp-1 compounds
EP2150308B1 (en) * 2007-05-09 2018-08-08 MetaCure Limited Analysis and regulation of food intake
US8423130B2 (en) * 2008-05-09 2013-04-16 Metacure Limited Optimization of thresholds for eating detection
US8865868B2 (en) 2008-08-06 2014-10-21 Novo Nordisk Healthcare Ag Conjugated proteins with prolonged in vivo efficacy
JP5816097B2 (ja) 2009-01-22 2015-11-18 ノヴォ・ノルディスク・ヘルス・ケア・アーゲー 安定な成長ホルモン化合物
EP2461831B1 (en) 2009-08-06 2018-11-21 Novo Nordisk Health Care AG Growth hormones with prolonged in-vivo efficacy
EP2482840A4 (en) * 2009-08-07 2013-06-26 Mannkind Corp VAL (8) GLP-1 COMPOSITION AND METHOD FOR THE TREATMENT OF REAGENTS AND / OR IRRITATION SYNDROME
CN118767115A (zh) 2010-01-22 2024-10-15 诺沃—诺迪斯克保健股份有限公司 体内功效延长的生长激素
US9211342B2 (en) 2010-01-22 2015-12-15 Novo Nordisk Healthcare Ag Stable growth hormone compounds resistant to proteolytic degradation
WO2011092710A2 (en) * 2010-02-01 2011-08-04 Metacure Limited Gastrointestinal electrical therapy
JP5827218B2 (ja) 2010-04-30 2015-12-02 株式会社三和化学研究所 生理活性物質等の生体内安定性向上のためのペプチド及び生体内安定性が向上した生理活性物質
UA116217C2 (uk) 2012-10-09 2018-02-26 Санофі Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
HRP20181300T1 (hr) 2012-12-21 2018-10-05 Sanofi Derivati eksendina-4 kao dvostruki glp1/gip- ili trostruki glp1/gip/glukagon agonisti
US11045523B2 (en) 2013-04-05 2021-06-29 Novo Nordisk Healthcare Ag Formulation of growth hormone albumin-binder conjugate

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6268343B1 (en) * 1996-08-30 2001-07-31 Novo Nordisk A/S Derivatives of GLP-1 analogs
JP2002510193A (ja) * 1997-03-31 2002-04-02 イーライ・リリー・アンド・カンパニー グルカゴン様ペプチド−1類似体
IL142707A0 (en) * 2000-04-27 2002-03-10 Pfizer Prod Inc Methods of treating obesity using a neurotensin receptor ligand

Similar Documents

Publication Publication Date Title
JP2005530732A5 (OSRAM)
US20240376175A1 (en) Novel GLP-1 Analogues
JP2007001987A5 (OSRAM)
ES2444622T3 (es) Derivado peptídico insulinotrópico en el que se ha modificado su aminoácido N-terminal
CN102711804B (zh) 包含glp-1激动剂和甲硫氨酸的药物组合物
RU2485135C2 (ru) Соединения оксинтомодулина (варианты), фармацевтическая композиция на их основе, способы лечения и профилактики ожирения и сопутствующих заболеваний (варианты) и лекарственное средство (варианты)
TW202415675A (zh) 腸促胰島素(incretin)類似物及其用途
JP2002526454A5 (OSRAM)
JP2007523881A5 (OSRAM)
PT1143989E (pt) Exendinas para supressão de glucagon
DK0512042T3 (da) GLP-1-analoger anvendelige ved diabetesbehandling
RU2007134156A (ru) Ацилированные glp-1 соединения
CN108271356A (zh) 肠降血糖素-胰岛素缀合物
AU2015349743B2 (en) ELP fusion proteins for controlled and sustained release
TWI353250B (en) Glp-1 pharmaceutical compositions
JP2015528795A5 (OSRAM)
US20180280480A1 (en) Compositions and peptides having dual glp-1r and glp-2r agonist activity
RU2752787C1 (ru) Пептидный аналог ацилированного оксинтомодулина
KR20230146040A (ko) 글루카곤 유사 펩타이드-1 수용체 길항물질
WO2017200944A1 (en) Glucagon receptor/glp-1 receptor selective analog polypeptides and methods of use thereof
WO2015180634A1 (zh) 用于治疗2型糖尿病的长效肠激素多肽类似物及应用
US20240058422A1 (en) Glucagon-like peptide-1 receptor antagonists
RU2008129731A (ru) Новые пептиды-т-хелперные антигенные детерминанты (thd)